MedTrace Logo

Celecoxib (Celebrex) in the Management of Acute Renal Colic

NCT00304317 · Status: WITHDRAWN · Phase: PHASE4 · Type: INTERVENTIONAL

Last updated 2017-01-24

No results posted yet for this study

Summary

The purpose of this trial is to quantify the amount Celebrex, a specific cyclooxygenase-2 (COX-2) inhibitor, when used for the management of acute renal colic for a ureteral stone will:

* reduce pain medication usage
* improve the percentage of spontaneous stone passage
* decrease the time to spontaneous passage, and
* shift the size distribution of stones passed towards larger sizes

Conditions

  • Ureteral Calculi

Interventions

DRUG

celecoxib

Take two capsules (400 mg) by mouth immediately, then take one capsule (200 mg) by mouth every 12 hours until gone.

OTHER

Placebo

Take two capsules by mouth immediately, then take one capsule by mouth every 12 hours until gone.

Sponsors & Collaborators

Principal Investigators

  • Manoj Monga, MD · University of Minnesota

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-03-31
Primary Completion
2008-08-31
Completion
2008-08-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00304317 on ClinicalTrials.gov